Investment in Trellus Health plc

28 May 2021

Intuitive Investments Group plc

Investment in Trellus Health plc 

Intuitive Investments Group plc (AIM: IIG) ("IIG" or the "Company"), a closed-end investment company focussed on the life sciences sector, announces an investment of £250,000 to acquire 625,000 ordinary shares of Trellus Health plc (AIM: TRLS) ("Trellus Health") at a price of 40 pence per share (the "Investment"). The Investment is part of Trellus Health's flotation and associated fundraising as announced by Trellus Health on 20 May 2021 (the "Fundraising").

Trellus Health is commercialising the provision of digital chronic condition management solutions for employers and health plans that utilise the scientifically validated GRITT™ resilience-based methodology and a proprietary HIPAA-compliant technology platform called TrellusElevate™ to coordinate and deliver care remotely via telemedicine. The Company is initially focused on Inflammatory Bowel Diseases (IBD), which include the chronic incurable conditions of Crohn's Disease and ulcerative colitis, but considers its approach to have potential utility and demand across many chronic conditions. 

As part of the Fundraising, David Evans has personally invested £100,000, Cormac Kilty has personally invested £100,000 and Robert Naylor has personally invested £100,000. Robert Naylor has a pre-exisiting holding of 89,394 Trellus A shares.  Accordingly, David Evans and Robert Naylor did not vote as a member of the Investment Team approving the Investment.

For further information, please contact:

About Intuitive Investments Group plc

The Company is a recently established investing company, seeking to provide investors with exposure to a portfolio concentrating on fast growing and/or high potential Life Sciences businesses operating predominantly in the UK, continental Europe and the US, utilising the Board's experience and in particular that of the Chairman, David Evans, to seek to generate capital growth over the long term for shareholders.

About Trellus Health plc (www.trellushealth.com)

Trellus Health is commercialising the provision of digital chronic condition management solutions for employers and health plans that utilise the scientifically validated GRITT™ resilience-based methodology and a proprietary HIPAA-compliant technology platform called TrellusElevate™ to coordinate and deliver personalised care remotely via telehealth. The Company is initially focused on Inflammatory Bowel Diseases ("IBD"), which includes the chronic incurable conditions of Crohn's Disease and ulcerative colitis, but considers its approach to have potential utility and demand across many chronic conditions.

The TrellusElevate™ platform is the Company's proprietary connected health platform that incorporates the GRITT™ methodology and learnings on resilience from clinical research and practice conducted at the Mount Sinai IBD Center for more than five years. The GRITT™ methodology and resilience-driven multidisciplinary care model have been scientifically validated to demonstrate meaningful improvements in patient outcomes and over 85 per cent. reduction in unplanned healthcare utilisation (emergency department visits and hospitalisations) which the directors of the Company believe indicates the potential for significant cost savings for healthcare payers.